Tranexamic acid in total knee replacement and total hip replacement – a single-center retrospective, observational study

Wojciech Konarski, Tomasz Poboży, Martyna Hordowicz

Background: Numerous strategies are used to decrease the risk of the need for [allogeneic blood transfusion (ABT)], including [tranexamic acid (TXA)]. Objective: In a single-center retrospective observational study, we have assessed the impact of TXA on the need and average volume of blood used during transfusion. Methods: We have reviewed medical records of a total of 491 patients undergoing arthroplasty in our hospital from Dec 2016 to Dec 2019. Results: 226 patients were administered TXA IV, and 265 did not receive an additional intervention. In the TXA group, 7/226 patients required ABT vs. 41/265 in the non-TXA group (p<0,001). The Non-TXA group required a significantly higher blood transfusion volume than the TXA group (mean 82,42 mL vs. 12,74 mL; p<0,001). Conclusion: We conclude that two doses of 1g TXA administered [intravenously (IV)] before incision and during skin suturing reduce the need for blood transfusion in patients undergoing JRS.

Streszczenie pochodzi z bazy OpenAlex (CC0) i może być w języku publikacji.